Saskia Rösch – VJRegenMed

Streamlining cell therapy manufacturing with CliniMACS Prodigy

Simon Ng — Thu, 28 Apr 2022 08:38:41 +0000

Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, gives an overview of CliniMACS Prodigy, a novel next-generation automated cell processing platform that aims to separate and process cell cultures for the manufacturing of cell therapies. The closed, scalable system enables the production of good manufacturing practice (GMP) compliant products of consistent quality in a safe and clean environment. CliniMACS Prodigy additionally is flexible in a centralized or decentralized setting and can be used for various cell types including induced pluripotent stem (iPS) cells, chimeric antigen receptor (CAR) T-cells and natural killer (NK) cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Implementing automation technology in the CGT space

Simon Ng — Thu, 28 Apr 2022 08:38:40 +0000

The advent of automation has brought improvements in the manufacturing of advanced therapies in terms of reducing the number of staff needed, cost, and safety. Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, discusses potential barriers developers might face in automating their manufacturing processes. Companies will need to make sure the product can be translated from a research to clinical setting, as well as if the reagents can be scaled-up if necessary. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Utilizing flow cytometry in CAR T-cell research

Simon Ng — Thu, 28 Apr 2022 08:38:38 +0000

Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, comments on the importance of flow cytometry in the characterization of chimeric antigen receptor (CAR) T-cells. Standardization of flow cytometry techniques is necessary to optimize CAR T-cell therapies, and Dr Rösch discusses automated workflow solutions offered by Miltenyi, as well as CAR detectors that can quantify CAR T-cells in a given sample. She additionally highlights a consortium that will create a gold standard for the analysis of engineered CAR T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Optimizing the upscaling and outscaling of CAR T-cell therapies

Simon Ng — Thu, 14 Apr 2022 15:56:43 +0000

Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, describes novel approaches to enhance chimeric antigen receptor (CAR) T-cell manufacturing. Upscaling can incur cost-related barriers, especially for T-cell receptor (TCR) and allogeneic therapies in solid tumor indications, and utilizing non-viral vectors as well as reducing the cultivation time may ameliorate the aforementioned issues. Developers additionally face issues in outscaling due to complications in material and documentation management, and Dr Rösch suggests decentralization as a potential solution. Regulatory authorities must also collaborate to expedite the development of T-cell therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Direct detection and isolation of CAR cells from patient samples

Simon Ng — Thu, 14 Apr 2022 15:56:42 +0000

Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, discusses strategies to isolate and identify chimeric antigen receptor (CAR) from patient samples for the purposes of quality control. Dr Rösch outlines a CAR detection agent that finds active CARs by detecting CD19, CD22, CD33, and B-cell maturation antigen (BCMA) in the product, as well as measure their transduction rate. Monitoring the efficacy of CAR T-cell therapies can additionally be carried out by assessing metabolome of CAR T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.